 Glenn Furuta
Concepts (720)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Eosinophilic Esophagitis | 125 | 2024 | 296 | 21.750 |
Why?
| | Eosinophilia | 78 | 2024 | 186 | 12.250 |
Why?
| | Eosinophils | 56 | 2023 | 278 | 8.240 |
Why?
| | Enteritis | 39 | 2024 | 82 | 6.470 |
Why?
| | Esophagitis | 32 | 2023 | 65 | 6.080 |
Why?
| | Gastritis | 38 | 2024 | 84 | 5.790 |
Why?
| | Esophagus | 38 | 2022 | 225 | 5.590 |
Why?
| | Gastroesophageal Reflux | 26 | 2022 | 234 | 2.840 |
Why?
| | Colitis | 19 | 2019 | 223 | 2.540 |
Why?
| | Proton Pump Inhibitors | 17 | 2022 | 96 | 2.390 |
Why?
| | Intestinal Mucosa | 25 | 2019 | 532 | 2.390 |
Why?
| | Esophagoscopy | 25 | 2023 | 184 | 1.960 |
Why?
| | Gastrointestinal Diseases | 10 | 2019 | 182 | 1.900 |
Why?
| | Food Hypersensitivity | 18 | 2023 | 251 | 1.790 |
Why?
| | Gastrointestinal Tract | 7 | 2019 | 169 | 1.770 |
Why?
| | Child | 115 | 2024 | 18423 | 1.710 |
Why?
| | Epithelial Cells | 17 | 2024 | 951 | 1.680 |
Why?
| | Endoscopy, Gastrointestinal | 16 | 2024 | 203 | 1.550 |
Why?
| | Humans | 237 | 2024 | 114711 | 1.460 |
Why?
| | Hypersensitivity | 11 | 2022 | 252 | 1.420 |
Why?
| | Anti-Inflammatory Agents | 13 | 2019 | 447 | 1.360 |
Why?
| | Microbiota | 5 | 2022 | 647 | 1.330 |
Why?
| | Inflammatory Bowel Diseases | 7 | 2022 | 284 | 1.280 |
Why?
| | Gastroenteritis | 7 | 2023 | 65 | 1.140 |
Why?
| | Adolescent | 67 | 2024 | 17856 | 1.110 |
Why?
| | Endoscopy | 6 | 2023 | 246 | 1.030 |
Why?
| | Child, Preschool | 50 | 2024 | 9119 | 1.020 |
Why?
| | Mucous Membrane | 8 | 2023 | 108 | 1.020 |
Why?
| | Esophageal Mucosa | 3 | 2019 | 17 | 0.950 |
Why?
| | Tight Junctions | 4 | 2024 | 68 | 0.940 |
Why?
| | Esophageal Stenosis | 8 | 2022 | 45 | 0.920 |
Why?
| | Mast Cells | 12 | 2022 | 116 | 0.900 |
Why?
| | Biopsy | 22 | 2023 | 1036 | 0.900 |
Why?
| | Diet Therapy | 5 | 2018 | 36 | 0.900 |
Why?
| | Quality of Life | 12 | 2023 | 2353 | 0.900 |
Why?
| | Virtual Reality | 2 | 2021 | 38 | 0.870 |
Why?
| | Adrenal Cortex Hormones | 9 | 2019 | 497 | 0.800 |
Why?
| | Adult | 65 | 2023 | 30562 | 0.800 |
Why?
| | Male | 94 | 2024 | 55669 | 0.790 |
Why?
| | Claudin-1 | 2 | 2019 | 21 | 0.780 |
Why?
| | Glucocorticoids | 8 | 2023 | 532 | 0.780 |
Why?
| | Allergens | 9 | 2023 | 413 | 0.760 |
Why?
| | Gastroenterology | 3 | 2020 | 159 | 0.750 |
Why?
| | Immunity, Mucosal | 3 | 2016 | 84 | 0.720 |
Why?
| | Diagnosis, Differential | 21 | 2021 | 1342 | 0.710 |
Why?
| | Female | 88 | 2024 | 59573 | 0.710 |
Why?
| | Severity of Illness Index | 14 | 2022 | 2540 | 0.710 |
Why?
| | Deglutition Disorders | 10 | 2023 | 118 | 0.700 |
Why?
| | Collagen | 4 | 2015 | 415 | 0.700 |
Why?
| | Colon | 7 | 2019 | 233 | 0.690 |
Why?
| | Peanut Hypersensitivity | 7 | 2017 | 197 | 0.680 |
Why?
| | Antibodies, Monoclonal | 6 | 2017 | 1264 | 0.670 |
Why?
| | Cytokines | 11 | 2020 | 1841 | 0.660 |
Why?
| | Inflammation | 15 | 2024 | 2480 | 0.650 |
Why?
| | Dilatation | 8 | 2022 | 60 | 0.640 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2019 | 249 | 0.630 |
Why?
| | Fibrosis | 4 | 2017 | 453 | 0.630 |
Why?
| | Prospective Studies | 19 | 2023 | 6220 | 0.620 |
Why?
| | Diet | 7 | 2022 | 1080 | 0.620 |
Why?
| | Leukocyte Count | 11 | 2021 | 293 | 0.620 |
Why?
| | Interleukin-5 | 3 | 2014 | 30 | 0.620 |
Why?
| | Animals | 52 | 2023 | 31710 | 0.620 |
Why?
| | Crohn Disease | 4 | 2020 | 196 | 0.610 |
Why?
| | GATA3 Transcription Factor | 2 | 2018 | 24 | 0.610 |
Why?
| | Eosinophil Granule Proteins | 4 | 2012 | 20 | 0.610 |
Why?
| | Epithelium | 8 | 2023 | 295 | 0.610 |
Why?
| | Tumor Necrosis Factor-alpha | 7 | 2013 | 1140 | 0.600 |
Why?
| | Infant | 31 | 2023 | 7969 | 0.570 |
Why?
| | Family | 5 | 2014 | 590 | 0.570 |
Why?
| | Intestines | 7 | 2021 | 326 | 0.560 |
Why?
| | Child Development Disorders, Pervasive | 3 | 2012 | 58 | 0.560 |
Why?
| | Fluticasone | 7 | 2023 | 87 | 0.560 |
Why?
| | Asthma | 7 | 2023 | 2029 | 0.550 |
Why?
| | Endoscopy, Digestive System | 6 | 2021 | 110 | 0.550 |
Why?
| | Receptors, CCR3 | 2 | 2018 | 8 | 0.540 |
Why?
| | Claudins | 3 | 2024 | 24 | 0.530 |
Why?
| | Probiotics | 1 | 2016 | 47 | 0.520 |
Why?
| | Arachis | 5 | 2017 | 146 | 0.510 |
Why?
| | Drug Discovery | 2 | 2017 | 123 | 0.510 |
Why?
| | Enterocolitis | 2 | 2013 | 33 | 0.510 |
Why?
| | Intestinal Diseases, Parasitic | 1 | 2015 | 11 | 0.500 |
Why?
| | Interleukin-33 | 1 | 2015 | 38 | 0.500 |
Why?
| | Peptides | 6 | 2018 | 848 | 0.500 |
Why?
| | Celiac Disease | 2 | 2015 | 264 | 0.490 |
Why?
| | Ileum | 1 | 2015 | 90 | 0.490 |
Why?
| | Administration, Oral | 5 | 2023 | 729 | 0.490 |
Why?
| | Retrospective Studies | 28 | 2024 | 12558 | 0.480 |
Why?
| | Gastrointestinal Agents | 3 | 2019 | 60 | 0.480 |
Why?
| | Signal Transduction | 9 | 2020 | 4517 | 0.480 |
Why?
| | Constipation | 2 | 2012 | 76 | 0.470 |
Why?
| | Interleukin-13 | 4 | 2021 | 122 | 0.470 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2023 | 663 | 0.460 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2014 | 9 | 0.460 |
Why?
| | Ileitis | 2 | 2011 | 26 | 0.460 |
Why?
| | Bottle Feeding | 1 | 2014 | 20 | 0.460 |
Why?
| | Steroids | 5 | 2023 | 144 | 0.450 |
Why?
| | Disease Models, Animal | 11 | 2017 | 3535 | 0.450 |
Why?
| | Receptors, Calcium-Sensing | 2 | 2012 | 5 | 0.440 |
Why?
| | Algorithms | 7 | 2022 | 1470 | 0.440 |
Why?
| | Patient Reported Outcome Measures | 3 | 2021 | 250 | 0.430 |
Why?
| | Monitoring, Physiologic | 2 | 2014 | 249 | 0.420 |
Why?
| | beta-Defensins | 1 | 2013 | 18 | 0.420 |
Why?
| | Immunotherapy | 3 | 2020 | 474 | 0.420 |
Why?
| | Mother-Child Relations | 1 | 2014 | 111 | 0.420 |
Why?
| | Young Adult | 21 | 2022 | 10472 | 0.420 |
Why?
| | Mice, Transgenic | 3 | 2019 | 1950 | 0.410 |
Why?
| | Mice | 29 | 2019 | 14872 | 0.410 |
Why?
| | Mucositis | 1 | 2012 | 18 | 0.400 |
Why?
| | Feeding Behavior | 5 | 2019 | 575 | 0.390 |
Why?
| | Consensus | 8 | 2022 | 539 | 0.390 |
Why?
| | Rare Diseases | 1 | 2012 | 89 | 0.390 |
Why?
| | Neutrophils | 8 | 2017 | 1176 | 0.380 |
Why?
| | Esophageal Diseases | 2 | 2008 | 24 | 0.380 |
Why?
| | Adrenal Insufficiency | 2 | 2022 | 26 | 0.370 |
Why?
| | Eosinophil Peroxidase | 3 | 2018 | 6 | 0.370 |
Why?
| | Hypoxia-Inducible Factor 1 | 6 | 2020 | 68 | 0.370 |
Why?
| | Breast Feeding | 1 | 2014 | 368 | 0.360 |
Why?
| | Dermatitis, Atopic | 1 | 2014 | 307 | 0.360 |
Why?
| | Cell Communication | 3 | 2017 | 280 | 0.350 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 9 | 2017 | 28 | 0.350 |
Why?
| | Food | 3 | 2020 | 160 | 0.340 |
Why?
| | Ribonucleases | 2 | 2000 | 52 | 0.330 |
Why?
| | Androstadienes | 3 | 2014 | 97 | 0.330 |
Why?
| | Blood Proteins | 3 | 2002 | 231 | 0.330 |
Why?
| | MicroRNAs | 3 | 2024 | 600 | 0.330 |
Why?
| | Interleukin-8 | 2 | 2000 | 237 | 0.330 |
Why?
| | Cell Degranulation | 5 | 2020 | 39 | 0.330 |
Why?
| | Dexamethasone | 7 | 2012 | 317 | 0.320 |
Why?
| | Biomarkers | 8 | 2022 | 3408 | 0.310 |
Why?
| | United States | 26 | 2023 | 12184 | 0.310 |
Why?
| | Biological Products | 2 | 2023 | 166 | 0.310 |
Why?
| | Treatment Outcome | 16 | 2023 | 9089 | 0.310 |
Why?
| | Diagnostic Techniques, Digestive System | 3 | 2018 | 11 | 0.310 |
Why?
| | Age Factors | 9 | 2020 | 2894 | 0.300 |
Why?
| | Practice Guidelines as Topic | 5 | 2020 | 1394 | 0.300 |
Why?
| | Immunoglobulin E | 8 | 2017 | 314 | 0.300 |
Why?
| | Patient Compliance | 1 | 2012 | 525 | 0.300 |
Why?
| | Budesonide | 3 | 2022 | 87 | 0.300 |
Why?
| | Nuclear Proteins | 4 | 2018 | 591 | 0.290 |
Why?
| | Fibroblasts | 3 | 2021 | 838 | 0.290 |
Why?
| | History, 20th Century | 3 | 2014 | 264 | 0.290 |
Why?
| | Pregnenediones | 2 | 2021 | 21 | 0.290 |
Why?
| | Gene Expression Regulation | 8 | 2021 | 2320 | 0.290 |
Why?
| | Deglutition | 2 | 2019 | 58 | 0.280 |
Why?
| | Case-Control Studies | 8 | 2022 | 3004 | 0.280 |
Why?
| | Eosinophil Major Basic Protein | 2 | 2008 | 6 | 0.280 |
Why?
| | Middle Aged | 23 | 2021 | 26740 | 0.270 |
Why?
| | Chemokine CCL24 | 2 | 2019 | 9 | 0.270 |
Why?
| | Th2 Cells | 3 | 2018 | 154 | 0.270 |
Why?
| | Barrett Esophagus | 1 | 2008 | 147 | 0.260 |
Why?
| | Biomedical Research | 4 | 2019 | 585 | 0.260 |
Why?
| | Evidence-Based Medicine | 3 | 2020 | 668 | 0.250 |
Why?
| | Surveys and Questionnaires | 8 | 2022 | 4624 | 0.250 |
Why?
| | Biological Assay | 1 | 2006 | 112 | 0.250 |
Why?
| | Esophagitis, Peptic | 2 | 2006 | 16 | 0.240 |
Why?
| | Milk Hypersensitivity | 2 | 2003 | 22 | 0.240 |
Why?
| | Anti-Allergic Agents | 3 | 2015 | 41 | 0.240 |
Why?
| | Caco-2 Cells | 5 | 2012 | 66 | 0.240 |
Why?
| | Endosonography | 2 | 2003 | 140 | 0.240 |
Why?
| | Mice, Inbred C57BL | 11 | 2017 | 4694 | 0.230 |
Why?
| | Cell Movement | 5 | 2018 | 869 | 0.230 |
Why?
| | Duodenitis | 1 | 2024 | 7 | 0.220 |
Why?
| | Neuropeptides | 2 | 2001 | 65 | 0.220 |
Why?
| | Baclofen | 1 | 2003 | 10 | 0.220 |
Why?
| | Practice Patterns, Physicians' | 3 | 2017 | 1177 | 0.220 |
Why?
| | Massage | 2 | 2014 | 42 | 0.220 |
Why?
| | History, 21st Century | 2 | 2014 | 159 | 0.220 |
Why?
| | Dermatologic Agents | 1 | 2023 | 57 | 0.210 |
Why?
| | Milk Proteins | 1 | 2003 | 36 | 0.210 |
Why?
| | Phenotype | 7 | 2022 | 2797 | 0.200 |
Why?
| | Homeostasis | 3 | 2021 | 573 | 0.200 |
Why?
| | Extracellular Matrix | 1 | 2006 | 436 | 0.200 |
Why?
| | Colitis, Microscopic | 1 | 2022 | 3 | 0.200 |
Why?
| | Infant, Newborn | 5 | 2023 | 5048 | 0.200 |
Why?
| | Hypoxia | 3 | 2024 | 958 | 0.200 |
Why?
| | Cell Line, Transformed | 2 | 2019 | 133 | 0.190 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1121 | 0.190 |
Why?
| | Tetraspanins | 1 | 2021 | 15 | 0.190 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2015 | 485 | 0.190 |
Why?
| | Administration, Topical | 3 | 2020 | 138 | 0.190 |
Why?
| | Sex Chromosomes | 1 | 2021 | 42 | 0.190 |
Why?
| | Oxazolone | 2 | 2012 | 5 | 0.190 |
Why?
| | Aneuploidy | 1 | 2021 | 85 | 0.180 |
Why?
| | Growth Substances | 1 | 2001 | 138 | 0.180 |
Why?
| | Neutrophil Activation | 2 | 2003 | 94 | 0.180 |
Why?
| | Esophageal Sphincter, Lower | 1 | 2020 | 10 | 0.180 |
Why?
| | Telemedicine | 2 | 2019 | 662 | 0.180 |
Why?
| | Intestine, Small | 2 | 2019 | 122 | 0.180 |
Why?
| | Gene Expression | 6 | 2021 | 1421 | 0.180 |
Why?
| | Mucins | 1 | 2001 | 61 | 0.180 |
Why?
| | Genetic Loci | 2 | 2021 | 262 | 0.180 |
Why?
| | Transition to Adult Care | 1 | 2021 | 62 | 0.180 |
Why?
| | RNA, Messenger | 6 | 2018 | 2553 | 0.180 |
Why?
| | Polysaccharide-Lyases | 1 | 2000 | 11 | 0.180 |
Why?
| | Chemokines | 2 | 2015 | 216 | 0.180 |
Why?
| | Esophageal Achalasia | 1 | 2020 | 25 | 0.180 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2000 | 21 | 0.180 |
Why?
| | Peroxidase | 2 | 2015 | 163 | 0.180 |
Why?
| | DNA-Binding Proteins | 3 | 2018 | 1314 | 0.180 |
Why?
| | Chemokines, CC | 1 | 2000 | 28 | 0.170 |
Why?
| | Genetic Predisposition to Disease | 4 | 2021 | 2087 | 0.170 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 238 | 0.170 |
Why?
| | Esophageal Motility Disorders | 2 | 2011 | 23 | 0.170 |
Why?
| | Nanoparticles | 3 | 2018 | 313 | 0.170 |
Why?
| | Dietary Exposure | 1 | 2019 | 7 | 0.170 |
Why?
| | Chemokine CCL26 | 1 | 2019 | 7 | 0.170 |
Why?
| | Feeding and Eating Disorders | 2 | 2018 | 103 | 0.170 |
Why?
| | Skin Tests | 6 | 2017 | 116 | 0.170 |
Why?
| | Genetic Association Studies | 1 | 2021 | 339 | 0.170 |
Why?
| | Models, Biological | 2 | 2008 | 1621 | 0.170 |
Why?
| | Immunity, Innate | 2 | 2020 | 720 | 0.170 |
Why?
| | Gastrostomy | 2 | 2018 | 91 | 0.160 |
Why?
| | Muscle Proteins | 1 | 2001 | 210 | 0.160 |
Why?
| | Anxiety | 2 | 2017 | 840 | 0.160 |
Why?
| | Nutritional Status | 3 | 2018 | 287 | 0.160 |
Why?
| | Enteral Nutrition | 1 | 2020 | 160 | 0.160 |
Why?
| | Nutrition Therapy | 1 | 2019 | 31 | 0.160 |
Why?
| | Time Factors | 5 | 2019 | 6114 | 0.160 |
Why?
| | Penicillamine | 1 | 1998 | 22 | 0.160 |
Why?
| | Hepatolenticular Degeneration | 1 | 1998 | 16 | 0.160 |
Why?
| | Integrins | 1 | 2019 | 79 | 0.160 |
Why?
| | Self Report | 3 | 2018 | 696 | 0.160 |
Why?
| | Anaphylaxis | 3 | 2011 | 144 | 0.160 |
Why?
| | Feasibility Studies | 2 | 2019 | 737 | 0.160 |
Why?
| | Protein Stability | 1 | 2019 | 157 | 0.160 |
Why?
| | Nephrotic Syndrome | 1 | 1998 | 24 | 0.160 |
Why?
| | Abscess | 2 | 2012 | 72 | 0.160 |
Why?
| | Stem Cell Factor | 1 | 1998 | 14 | 0.160 |
Why?
| | Chelating Agents | 1 | 1998 | 65 | 0.160 |
Why?
| | Arachidonic Acids | 1 | 1998 | 56 | 0.150 |
Why?
| | Radiography | 4 | 2015 | 812 | 0.150 |
Why?
| | Chromosomes, Human, Pair 16 | 1 | 2018 | 30 | 0.150 |
Why?
| | Cell Hypoxia | 5 | 2004 | 221 | 0.150 |
Why?
| | Clinical Trials as Topic | 3 | 2019 | 932 | 0.150 |
Why?
| | Mice, Inbred Strains | 4 | 2011 | 396 | 0.150 |
Why?
| | Colonic Diseases | 1 | 2018 | 25 | 0.150 |
Why?
| | Population Groups | 1 | 2018 | 57 | 0.150 |
Why?
| | Prevalence | 5 | 2021 | 2251 | 0.150 |
Why?
| | Hypersensitivity, Immediate | 1 | 2018 | 46 | 0.150 |
Why?
| | Respiratory Hypersensitivity | 1 | 2018 | 60 | 0.150 |
Why?
| | Placebos | 1 | 2018 | 197 | 0.150 |
Why?
| | Aged | 12 | 2021 | 19075 | 0.150 |
Why?
| | Histological Techniques | 1 | 2018 | 40 | 0.150 |
Why?
| | Internet | 1 | 2022 | 596 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2019 | 1214 | 0.140 |
Why?
| | Cell Line | 7 | 2018 | 2637 | 0.140 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2003 | 534 | 0.140 |
Why?
| | Transcription Factors | 2 | 2004 | 1528 | 0.140 |
Why?
| | Eczema | 2 | 2017 | 81 | 0.140 |
Why?
| | Chemokine CCL11 | 2 | 2011 | 22 | 0.140 |
Why?
| | Anesthetics, Intravenous | 1 | 2017 | 27 | 0.140 |
Why?
| | Medical History Taking | 2 | 2015 | 114 | 0.140 |
Why?
| | Cells, Cultured | 8 | 2017 | 3886 | 0.140 |
Why?
| | Interdisciplinary Research | 1 | 2017 | 25 | 0.140 |
Why?
| | Hydrogen-Ion Concentration | 4 | 2008 | 511 | 0.140 |
Why?
| | Permeability | 3 | 2011 | 149 | 0.140 |
Why?
| | Propofol | 1 | 2017 | 43 | 0.140 |
Why?
| | Receptor, Adenosine A2B | 2 | 2015 | 32 | 0.140 |
Why?
| | Quality Indicators, Health Care | 1 | 2019 | 287 | 0.140 |
Why?
| | Reproducibility of Results | 7 | 2022 | 2766 | 0.140 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2017 | 153 | 0.130 |
Why?
| | Dietetics | 2 | 2017 | 22 | 0.130 |
Why?
| | Endothelial Cells | 1 | 2021 | 687 | 0.130 |
Why?
| | Serotonin | 1 | 1998 | 292 | 0.130 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 140 | 0.130 |
Why?
| | Environmental Exposure | 1 | 2019 | 372 | 0.130 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 97 | 0.130 |
Why?
| | Secale | 1 | 2015 | 1 | 0.130 |
Why?
| | Hordeum | 1 | 2015 | 2 | 0.130 |
Why?
| | Meals | 1 | 2017 | 104 | 0.130 |
Why?
| | Triticum | 1 | 2015 | 9 | 0.130 |
Why?
| | Ubiquitin-Activating Enzymes | 1 | 2016 | 13 | 0.130 |
Why?
| | Myeloid Cells | 1 | 2017 | 126 | 0.130 |
Why?
| | Gastroenterologists | 1 | 2016 | 18 | 0.130 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2017 | 144 | 0.130 |
Why?
| | Bacterial Physiological Phenomena | 1 | 2016 | 57 | 0.130 |
Why?
| | Inflammasomes | 1 | 2017 | 115 | 0.130 |
Why?
| | Glutens | 1 | 2015 | 56 | 0.130 |
Why?
| | Helminths | 1 | 2015 | 7 | 0.130 |
Why?
| | Helminthiasis | 1 | 2015 | 10 | 0.130 |
Why?
| | Remission Induction | 4 | 2020 | 233 | 0.120 |
Why?
| | Lung | 2 | 2018 | 3561 | 0.120 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2015 | 26 | 0.120 |
Why?
| | Vascular Remodeling | 1 | 2017 | 153 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 923 | 0.120 |
Why?
| | Respiratory System | 1 | 2016 | 137 | 0.120 |
Why?
| | Primary Prevention | 1 | 2017 | 172 | 0.120 |
Why?
| | Patient Preference | 2 | 2022 | 167 | 0.120 |
Why?
| | Polymorphism, Genetic | 1 | 2018 | 610 | 0.120 |
Why?
| | Fibronectins | 1 | 2015 | 108 | 0.120 |
Why?
| | Mice, Knockout | 5 | 2017 | 2570 | 0.120 |
Why?
| | STAT6 Transcription Factor | 1 | 2014 | 22 | 0.120 |
Why?
| | Desmosomes | 1 | 2014 | 20 | 0.120 |
Why?
| | Constriction, Pathologic | 1 | 2015 | 208 | 0.120 |
Why?
| | Genetic Markers | 1 | 2016 | 320 | 0.120 |
Why?
| | Cost of Illness | 2 | 2014 | 254 | 0.120 |
Why?
| | Calpain | 1 | 2014 | 53 | 0.120 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1518 | 0.120 |
Why?
| | Prognosis | 3 | 2018 | 3330 | 0.120 |
Why?
| | Cell Adhesion Molecules | 1 | 2015 | 168 | 0.120 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2016 | 194 | 0.120 |
Why?
| | Receptors, Interleukin-5 | 1 | 2014 | 5 | 0.120 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2014 | 55 | 0.120 |
Why?
| | HT29 Cells | 2 | 2012 | 35 | 0.120 |
Why?
| | Medication Adherence | 1 | 2019 | 532 | 0.120 |
Why?
| | History, 19th Century | 1 | 2014 | 54 | 0.110 |
Why?
| | Allergy and Immunology | 3 | 2020 | 51 | 0.110 |
Why?
| | Ambulatory Care | 1 | 2018 | 478 | 0.110 |
Why?
| | Rhinitis, Allergic | 1 | 2014 | 35 | 0.110 |
Why?
| | RNA, Bacterial | 1 | 2015 | 174 | 0.110 |
Why?
| | Parents | 2 | 2020 | 1186 | 0.110 |
Why?
| | Acute Lung Injury | 1 | 2017 | 299 | 0.110 |
Why?
| | Sensitivity and Specificity | 3 | 2013 | 1695 | 0.110 |
Why?
| | Symptom Assessment | 1 | 2015 | 119 | 0.110 |
Why?
| | Ileal Neoplasms | 1 | 1993 | 4 | 0.110 |
Why?
| | Ileocecal Valve | 1 | 1993 | 4 | 0.110 |
Why?
| | Twins, Dizygotic | 1 | 2014 | 182 | 0.110 |
Why?
| | Predictive Value of Tests | 4 | 2022 | 1796 | 0.110 |
Why?
| | Autophagy | 1 | 2016 | 235 | 0.110 |
Why?
| | Intussusception | 1 | 1993 | 27 | 0.110 |
Why?
| | Immunoglobulin G | 3 | 2018 | 770 | 0.110 |
Why?
| | Leiomyosarcoma | 1 | 1993 | 26 | 0.110 |
Why?
| | Drug Resistance | 1 | 2014 | 158 | 0.110 |
Why?
| | Gastrointestinal Microbiome | 2 | 2017 | 501 | 0.110 |
Why?
| | Twins, Monozygotic | 1 | 2014 | 210 | 0.110 |
Why?
| | Calcium | 3 | 2012 | 1108 | 0.110 |
Why?
| | Polypharmacy | 1 | 2014 | 74 | 0.110 |
Why?
| | Eosinophil Cationic Protein | 2 | 2012 | 9 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2018 | 1842 | 0.110 |
Why?
| | Electric Impedance | 3 | 2017 | 100 | 0.110 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2387 | 0.110 |
Why?
| | Cystic Fibrosis | 2 | 2021 | 955 | 0.110 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 183 | 0.110 |
Why?
| | Interferon-gamma | 1 | 2016 | 719 | 0.100 |
Why?
| | Host-Pathogen Interactions | 2 | 2020 | 295 | 0.100 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2012 | 26 | 0.100 |
Why?
| | Expressed Sequence Tags | 1 | 2012 | 38 | 0.100 |
Why?
| | Immune Tolerance | 2 | 2017 | 323 | 0.100 |
Why?
| | Lysophospholipase | 1 | 2012 | 10 | 0.100 |
Why?
| | Gastric Mucosa | 2 | 2011 | 46 | 0.100 |
Why?
| | Adaptation, Psychological | 2 | 2014 | 547 | 0.100 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 551 | 0.100 |
Why?
| | Inflammation Mediators | 1 | 2015 | 477 | 0.100 |
Why?
| | Health Status Indicators | 1 | 2013 | 156 | 0.100 |
Why?
| | Schools | 2 | 2013 | 399 | 0.100 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 146 | 0.100 |
Why?
| | Esophagogastric Junction | 2 | 2020 | 42 | 0.100 |
Why?
| | Food, Formulated | 2 | 2023 | 14 | 0.100 |
Why?
| | Genes, Bacterial | 1 | 2012 | 157 | 0.100 |
Why?
| | Herpesvirus 4, Human | 1 | 2012 | 125 | 0.100 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 164 | 0.100 |
Why?
| | Diet Surveys | 1 | 2012 | 78 | 0.100 |
Why?
| | Eating | 1 | 2014 | 344 | 0.100 |
Why?
| | Genome, Bacterial | 1 | 2012 | 106 | 0.100 |
Why?
| | Quality Improvement | 1 | 2019 | 950 | 0.100 |
Why?
| | Endpoint Determination | 2 | 2013 | 68 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 314 | 0.100 |
Why?
| | Neoplasm Proteins | 1 | 2014 | 385 | 0.100 |
Why?
| | Repressor Proteins | 1 | 2014 | 366 | 0.100 |
Why?
| | Metagenome | 1 | 2012 | 122 | 0.100 |
Why?
| | Patient Satisfaction | 1 | 2015 | 578 | 0.090 |
Why?
| | Child Behavior | 1 | 2013 | 219 | 0.090 |
Why?
| | Up-Regulation | 2 | 2012 | 808 | 0.090 |
Why?
| | Specimen Handling | 1 | 2012 | 156 | 0.090 |
Why?
| | Phosphorylation | 3 | 2012 | 1569 | 0.090 |
Why?
| | Cyclosporine | 3 | 1997 | 161 | 0.090 |
Why?
| | Nerve Growth Factors | 1 | 2011 | 71 | 0.090 |
Why?
| | Neutrophil Infiltration | 1 | 2011 | 96 | 0.090 |
Why?
| | Switzerland | 3 | 2015 | 17 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 796 | 0.090 |
Why?
| | Antigens, CD1 | 2 | 2002 | 57 | 0.090 |
Why?
| | Th1-Th2 Balance | 1 | 2010 | 9 | 0.090 |
Why?
| | Enzyme Activation | 1 | 2012 | 785 | 0.090 |
Why?
| | Caregivers | 1 | 2017 | 717 | 0.090 |
Why?
| | Feeding and Eating Disorders of Childhood | 1 | 2010 | 6 | 0.090 |
Why?
| | Glycoproteins | 1 | 2012 | 304 | 0.090 |
Why?
| | Professional Role | 1 | 2012 | 149 | 0.090 |
Why?
| | Risk Factors | 6 | 2022 | 8634 | 0.090 |
Why?
| | Equipment Design | 1 | 2012 | 508 | 0.090 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2012 | 167 | 0.090 |
Why?
| | HEK293 Cells | 1 | 2012 | 591 | 0.090 |
Why?
| | Transfection | 1 | 2012 | 866 | 0.090 |
Why?
| | RNA, Small Interfering | 3 | 2021 | 535 | 0.090 |
Why?
| | Sleep Wake Disorders | 1 | 2013 | 233 | 0.090 |
Why?
| | Transforming Growth Factor beta | 2 | 2012 | 448 | 0.090 |
Why?
| | Zollinger-Ellison Syndrome | 1 | 1989 | 2 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2017 | 944 | 0.080 |
Why?
| | Models, Genetic | 1 | 2012 | 562 | 0.080 |
Why?
| | Esophageal pH Monitoring | 1 | 2009 | 23 | 0.080 |
Why?
| | Cohort Studies | 4 | 2020 | 4895 | 0.080 |
Why?
| | Sequence Analysis, DNA | 1 | 2012 | 723 | 0.080 |
Why?
| | Follow-Up Studies | 5 | 2019 | 4411 | 0.080 |
Why?
| | Foreign Bodies | 1 | 2011 | 96 | 0.080 |
Why?
| | Pilot Projects | 1 | 2014 | 1373 | 0.080 |
Why?
| | Health Status | 1 | 2014 | 722 | 0.080 |
Why?
| | Th1 Cells | 1 | 2010 | 123 | 0.080 |
Why?
| | Manometry | 1 | 2009 | 89 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 282 | 0.080 |
Why?
| | Fibroblast Growth Factor 9 | 1 | 2008 | 2 | 0.080 |
Why?
| | Integrin beta1 | 1 | 2008 | 17 | 0.080 |
Why?
| | Gastrectomy | 1 | 1989 | 82 | 0.080 |
Why?
| | Chemotactic Factors, Eosinophil | 2 | 2017 | 6 | 0.080 |
Why?
| | Advisory Committees | 2 | 2020 | 208 | 0.080 |
Why?
| | Diarrhea | 1 | 2010 | 171 | 0.080 |
Why?
| | Abdominal Pain | 1 | 2010 | 135 | 0.080 |
Why?
| | 5'-Nucleotidase | 1 | 2008 | 35 | 0.080 |
Why?
| | Chronic Disease | 2 | 2011 | 1579 | 0.080 |
Why?
| | Gastric Acidity Determination | 1 | 2008 | 7 | 0.080 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2009 | 195 | 0.080 |
Why?
| | Gastric Acid | 1 | 2008 | 13 | 0.080 |
Why?
| | Social Support | 1 | 2012 | 529 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2009 | 206 | 0.070 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2008 | 26 | 0.070 |
Why?
| | Paneth Cells | 1 | 2008 | 17 | 0.070 |
Why?
| | Immunohistochemistry | 3 | 2012 | 1629 | 0.070 |
Why?
| | Chemotaxis, Leukocyte | 2 | 2006 | 130 | 0.070 |
Why?
| | Stomach | 2 | 2019 | 102 | 0.070 |
Why?
| | Lymphoid Tissue | 1 | 2008 | 62 | 0.070 |
Why?
| | Forecasting | 2 | 2019 | 330 | 0.070 |
Why?
| | Eosinophil-Derived Neurotoxin | 2 | 2012 | 3 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2012 | 680 | 0.070 |
Why?
| | Precision Medicine | 1 | 2010 | 337 | 0.070 |
Why?
| | Immunoglobulin A | 1 | 2008 | 166 | 0.070 |
Why?
| | Dextran Sulfate | 2 | 2017 | 70 | 0.070 |
Why?
| | Disease Susceptibility | 2 | 2020 | 316 | 0.070 |
Why?
| | Wound Healing | 1 | 2008 | 258 | 0.070 |
Why?
| | Incidence | 2 | 2019 | 2314 | 0.070 |
Why?
| | Antibody Formation | 1 | 2008 | 266 | 0.070 |
Why?
| | Nutritional Support | 1 | 2006 | 27 | 0.070 |
Why?
| | Flow Cytometry | 3 | 2016 | 1083 | 0.070 |
Why?
| | Terminology as Topic | 1 | 2007 | 187 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 4411 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2012 | 763 | 0.060 |
Why?
| | Monocytes | 2 | 2020 | 504 | 0.060 |
Why?
| | Blood Platelets | 1 | 2008 | 351 | 0.060 |
Why?
| | Gels | 1 | 2006 | 72 | 0.060 |
Why?
| | Exudates and Transudates | 1 | 2005 | 12 | 0.060 |
Why?
| | Disease Management | 2 | 2020 | 560 | 0.060 |
Why?
| | Depression | 1 | 2013 | 1135 | 0.060 |
Why?
| | Hydrocortisone | 2 | 2020 | 267 | 0.060 |
Why?
| | Disease Progression | 2 | 2012 | 2382 | 0.060 |
Why?
| | Child Nutrition Disorders | 2 | 2018 | 16 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 750 | 0.060 |
Why?
| | Membrane Proteins | 2 | 2018 | 1019 | 0.060 |
Why?
| | Genetic Testing | 2 | 2021 | 381 | 0.060 |
Why?
| | Leukemic Infiltration | 1 | 2003 | 5 | 0.060 |
Why?
| | Sigmoidoscopy | 1 | 2003 | 10 | 0.060 |
Why?
| | Daunorubicin | 1 | 2003 | 24 | 0.060 |
Why?
| | Physicians | 1 | 2012 | 772 | 0.060 |
Why?
| | Thioguanine | 1 | 2003 | 19 | 0.060 |
Why?
| | Adenine Nucleotides | 1 | 2003 | 18 | 0.060 |
Why?
| | Health Surveys | 2 | 2017 | 443 | 0.060 |
Why?
| | Receptors, Purinergic P1 | 1 | 2003 | 24 | 0.050 |
Why?
| | Leukocyte Common Antigens | 1 | 2003 | 75 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2013 | 2286 | 0.050 |
Why?
| | Cytarabine | 1 | 2003 | 51 | 0.050 |
Why?
| | Cell Cycle | 1 | 2006 | 542 | 0.050 |
Why?
| | Pyrophosphatases | 1 | 2003 | 22 | 0.050 |
Why?
| | Etoposide | 1 | 2003 | 148 | 0.050 |
Why?
| | Digestive System | 1 | 2003 | 27 | 0.050 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2003 | 102 | 0.050 |
Why?
| | Pain | 2 | 2022 | 705 | 0.050 |
Why?
| | Recombinant Proteins | 2 | 2008 | 1230 | 0.050 |
Why?
| | Genome-Wide Association Study | 2 | 2021 | 1177 | 0.050 |
Why?
| | Patient Outcome Assessment | 1 | 2023 | 122 | 0.050 |
Why?
| | Adenosine | 1 | 2003 | 203 | 0.050 |
Why?
| | Trefoil Factor-2 | 1 | 2001 | 3 | 0.050 |
Why?
| | Trefoil Factor-3 | 1 | 2001 | 5 | 0.050 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2021 | 51 | 0.050 |
Why?
| | Myenteric Plexus | 1 | 2020 | 4 | 0.050 |
Why?
| | Cell Culture Techniques | 2 | 2017 | 343 | 0.050 |
Why?
| | Lymphocytes | 1 | 2003 | 330 | 0.050 |
Why?
| | Base Sequence | 3 | 2017 | 2114 | 0.050 |
Why?
| | Rural Health | 1 | 2021 | 67 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2021 | 172 | 0.050 |
Why?
| | Klinefelter Syndrome | 1 | 2021 | 50 | 0.050 |
Why?
| | Recurrence | 1 | 2024 | 935 | 0.050 |
Why?
| | Gene Silencing | 1 | 2021 | 171 | 0.050 |
Why?
| | Weight Gain | 2 | 2014 | 453 | 0.050 |
Why?
| | Ubiquitins | 1 | 2000 | 31 | 0.050 |
Why?
| | Sex Factors | 2 | 2017 | 1715 | 0.040 |
Why?
| | International Cooperation | 1 | 2021 | 171 | 0.040 |
Why?
| | CD18 Antigens | 1 | 2000 | 33 | 0.040 |
Why?
| | Acute Disease | 2 | 2015 | 911 | 0.040 |
Why?
| | Cysteine Endopeptidases | 1 | 2000 | 60 | 0.040 |
Why?
| | Multienzyme Complexes | 1 | 2000 | 64 | 0.040 |
Why?
| | HeLa Cells | 3 | 2008 | 562 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2005 | 688 | 0.040 |
Why?
| | Dogs | 1 | 2001 | 334 | 0.040 |
Why?
| | Bone Marrow Cells | 2 | 1998 | 267 | 0.040 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2000 | 127 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2000 | 201 | 0.040 |
Why?
| | Dehydroepiandrosterone Sulfate | 1 | 2020 | 45 | 0.040 |
Why?
| | Erythema | 1 | 2019 | 25 | 0.040 |
Why?
| | Amino Acids | 1 | 2023 | 448 | 0.040 |
Why?
| | Muscle, Smooth | 1 | 2000 | 144 | 0.040 |
Why?
| | Ulcer | 1 | 2019 | 28 | 0.040 |
Why?
| | Patient Transfer | 1 | 2021 | 143 | 0.040 |
Why?
| | Autocrine Communication | 1 | 1999 | 42 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2002 | 778 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 146 | 0.040 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2020 | 128 | 0.040 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2019 | 106 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2020 | 455 | 0.040 |
Why?
| | Immunomodulation | 1 | 2020 | 84 | 0.040 |
Why?
| | Trientine | 1 | 1998 | 1 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2020 | 183 | 0.040 |
Why?
| | Retreatment | 1 | 1998 | 67 | 0.040 |
Why?
| | Cromolyn Sodium | 1 | 1998 | 13 | 0.040 |
Why?
| | Organizations | 1 | 2018 | 19 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2014 | 1660 | 0.040 |
Why?
| | Ionophores | 1 | 1998 | 22 | 0.040 |
Why?
| | Diffusion of Innovation | 1 | 2019 | 93 | 0.040 |
Why?
| | Concanavalin A | 1 | 1998 | 74 | 0.040 |
Why?
| | Edema | 1 | 1999 | 119 | 0.040 |
Why?
| | Nutrition Assessment | 2 | 2010 | 75 | 0.040 |
Why?
| | Models, Animal | 2 | 2016 | 344 | 0.040 |
Why?
| | Histamine | 1 | 1998 | 56 | 0.040 |
Why?
| | Intersectoral Collaboration | 1 | 2018 | 56 | 0.040 |
Why?
| | Lectins, C-Type | 1 | 2018 | 61 | 0.040 |
Why?
| | Monosaccharide Transport Proteins | 1 | 2018 | 45 | 0.040 |
Why?
| | Endopeptidases | 1 | 1998 | 71 | 0.040 |
Why?
| | Lipids | 1 | 2002 | 580 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2019 | 116 | 0.040 |
Why?
| | Culture Media, Conditioned | 1 | 1998 | 105 | 0.040 |
Why?
| | Delayed-Action Preparations | 1 | 2019 | 159 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2019 | 149 | 0.040 |
Why?
| | Visual Analog Scale | 1 | 2018 | 31 | 0.040 |
Why?
| | Anti-Bacterial Agents | 2 | 2009 | 1482 | 0.040 |
Why?
| | Interleukin-10 | 1 | 1999 | 299 | 0.040 |
Why?
| | Hyperplasia | 1 | 2018 | 163 | 0.040 |
Why?
| | RNA Transport | 1 | 2017 | 23 | 0.040 |
Why?
| | GTP-Binding Proteins | 1 | 2018 | 139 | 0.040 |
Why?
| | Loeys-Dietz Syndrome | 1 | 2017 | 6 | 0.040 |
Why?
| | Colorado | 2 | 2017 | 4100 | 0.040 |
Why?
| | Skin Irritancy Tests | 1 | 2017 | 3 | 0.040 |
Why?
| | Anthropometry | 1 | 2018 | 183 | 0.040 |
Why?
| | Ehlers-Danlos Syndrome | 1 | 2017 | 14 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 88 | 0.040 |
Why?
| | Contraindications, Drug | 1 | 2017 | 6 | 0.040 |
Why?
| | Hirschsprung Disease | 1 | 1999 | 90 | 0.040 |
Why?
| | Receptors, CCR2 | 1 | 2017 | 28 | 0.040 |
Why?
| | Attitude to Health | 1 | 2020 | 406 | 0.040 |
Why?
| | Pennsylvania | 1 | 2017 | 94 | 0.040 |
Why?
| | Observer Variation | 1 | 2018 | 296 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2003 | 847 | 0.030 |
Why?
| | Societies, Scientific | 1 | 2017 | 47 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2017 | 176 | 0.030 |
Why?
| | Nutritional Sciences | 1 | 2017 | 37 | 0.030 |
Why?
| | Dendritic Cells | 1 | 2020 | 435 | 0.030 |
Why?
| | Pentoxifylline | 1 | 1996 | 21 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 301 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 664 | 0.030 |
Why?
| | Egg Hypersensitivity | 1 | 2017 | 45 | 0.030 |
Why?
| | Cooperative Behavior | 1 | 2018 | 381 | 0.030 |
Why?
| | Autophagy-Related Protein 7 | 1 | 2016 | 5 | 0.030 |
Why?
| | Hematopoiesis | 1 | 2017 | 171 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2018 | 473 | 0.030 |
Why?
| | Chloroquine | 1 | 2016 | 52 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 1356 | 0.030 |
Why?
| | Skin Diseases | 2 | 2012 | 122 | 0.030 |
Why?
| | Trans-Activators | 1 | 2018 | 367 | 0.030 |
Why?
| | Cross Reactions | 1 | 2015 | 118 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 1998 | 993 | 0.030 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2017 | 482 | 0.030 |
Why?
| | Lipopolysaccharides | 2 | 2002 | 823 | 0.030 |
Why?
| | Mouth | 1 | 2015 | 70 | 0.030 |
Why?
| | Image-Guided Biopsy | 1 | 2015 | 31 | 0.030 |
Why?
| | In Situ Nick-End Labeling | 1 | 2015 | 119 | 0.030 |
Why?
| | Risk Reduction Behavior | 1 | 2017 | 201 | 0.030 |
Why?
| | Antibodies | 1 | 2017 | 371 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 594 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 274 | 0.030 |
Why?
| | Diagnostic Self Evaluation | 1 | 2015 | 22 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2021 | 800 | 0.030 |
Why?
| | Patient Acuity | 1 | 2015 | 42 | 0.030 |
Why?
| | Bacteria | 1 | 2021 | 725 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 1997 | 1144 | 0.030 |
Why?
| | Child Health Services | 1 | 2017 | 176 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2017 | 370 | 0.030 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2015 | 128 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2020 | 731 | 0.030 |
Why?
| | Machine Learning | 1 | 2018 | 316 | 0.030 |
Why?
| | Proteins | 1 | 2000 | 908 | 0.030 |
Why?
| | Keratinocytes | 1 | 2016 | 216 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1448 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2002 | 1737 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 1998 | 1037 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2014 | 135 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 442 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2021 | 1880 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2015 | 397 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2015 | 345 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2015 | 292 | 0.030 |
Why?
| | Ileal Diseases | 1 | 1993 | 9 | 0.030 |
Why?
| | Leukocytes | 1 | 1995 | 276 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 1996 | 493 | 0.030 |
Why?
| | Appetite | 1 | 2013 | 52 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 521 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2015 | 337 | 0.030 |
Why?
| | Neisseria meningitidis | 1 | 1993 | 18 | 0.030 |
Why?
| | Meningococcal Infections | 1 | 1993 | 20 | 0.030 |
Why?
| | Macrophages | 1 | 2020 | 1263 | 0.030 |
Why?
| | Protein Binding | 1 | 2018 | 1890 | 0.030 |
Why?
| | Transcription, Genetic | 3 | 2008 | 1313 | 0.030 |
Why?
| | Nasal Lavage Fluid | 1 | 2012 | 11 | 0.030 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 1993 | 58 | 0.030 |
Why?
| | Antigens, Bacterial | 1 | 1993 | 112 | 0.030 |
Why?
| | Sinusitis | 2 | 2012 | 174 | 0.030 |
Why?
| | Blotting, Western | 1 | 2015 | 1147 | 0.030 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2012 | 15 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 1996 | 646 | 0.020 |
Why?
| | Prednisone | 1 | 2013 | 229 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 439 | 0.020 |
Why?
| | Pneumonia | 1 | 2017 | 568 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 718 | 0.020 |
Why?
| | Linear Models | 1 | 2014 | 768 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2015 | 1226 | 0.020 |
Why?
| | Transcriptome | 1 | 2017 | 726 | 0.020 |
Why?
| | Vimentin | 1 | 2012 | 58 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2015 | 6346 | 0.020 |
Why?
| | Netrin-1 | 1 | 2011 | 11 | 0.020 |
Why?
| | Keratins | 1 | 2012 | 176 | 0.020 |
Why?
| | Transendothelial and Transepithelial Migration | 1 | 2011 | 29 | 0.020 |
Why?
| | Cell Differentiation | 1 | 1998 | 1701 | 0.020 |
Why?
| | Heartburn | 1 | 2011 | 11 | 0.020 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2011 | 28 | 0.020 |
Why?
| | Respiratory Tract Diseases | 1 | 2012 | 138 | 0.020 |
Why?
| | Food Labeling | 1 | 2011 | 17 | 0.020 |
Why?
| | DNA Primers | 2 | 2003 | 510 | 0.020 |
Why?
| | Rhinitis | 1 | 2012 | 128 | 0.020 |
Why?
| | Computational Biology | 1 | 2014 | 530 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1131 | 0.020 |
Why?
| | Sputum | 1 | 2012 | 286 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2012 | 620 | 0.020 |
Why?
| | Rats | 1 | 1998 | 4959 | 0.020 |
Why?
| | Caseins | 1 | 2010 | 19 | 0.020 |
Why?
| | Diet, Protein-Restricted | 1 | 2010 | 10 | 0.020 |
Why?
| | Emergencies | 1 | 2011 | 146 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2011 | 217 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2016 | 1076 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2012 | 590 | 0.020 |
Why?
| | Colistin | 1 | 2009 | 8 | 0.020 |
Why?
| | Radiography, Abdominal | 1 | 2010 | 32 | 0.020 |
Why?
| | Diet, Gluten-Free | 1 | 2010 | 30 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2010 | 271 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2011 | 641 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2011 | 243 | 0.020 |
Why?
| | Mitochondrial Diseases | 1 | 2010 | 77 | 0.020 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2008 | 21 | 0.020 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2008 | 12 | 0.020 |
Why?
| | Databases, Genetic | 1 | 2010 | 206 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2009 | 134 | 0.020 |
Why?
| | Vancomycin | 1 | 2009 | 75 | 0.020 |
Why?
| | Sleep | 1 | 2013 | 632 | 0.020 |
Why?
| | Adolescent Behavior | 1 | 2013 | 488 | 0.020 |
Why?
| | Physical Examination | 1 | 2010 | 222 | 0.020 |
Why?
| | Child Behavior Disorders | 1 | 2010 | 131 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2010 | 313 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2008 | 132 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 2968 | 0.020 |
Why?
| | Nasal Polyps | 1 | 1987 | 49 | 0.020 |
Why?
| | Health Education | 1 | 2010 | 323 | 0.020 |
Why?
| | Weight Loss | 1 | 2011 | 642 | 0.020 |
Why?
| | Zebrafish | 1 | 2009 | 412 | 0.020 |
Why?
| | Patient Care Team | 1 | 2010 | 517 | 0.020 |
Why?
| | Health Personnel | 1 | 2010 | 574 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2004 | 257 | 0.010 |
Why?
| | Apyrase | 1 | 2003 | 14 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 2004 | 176 | 0.010 |
Why?
| | Cell Membrane Permeability | 1 | 2003 | 83 | 0.010 |
Why?
| | Hydrolysis | 1 | 2003 | 173 | 0.010 |
Why?
| | Microcirculation | 1 | 2003 | 135 | 0.010 |
Why?
| | Gene Deletion | 1 | 2004 | 356 | 0.010 |
Why?
| | Adenosine Triphosphatases | 1 | 2003 | 153 | 0.010 |
Why?
| | Passive Cutaneous Anaphylaxis | 1 | 2002 | 5 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2008 | 2711 | 0.010 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2002 | 75 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2187 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2012 | 1728 | 0.010 |
Why?
| | Antigens, CD | 1 | 2003 | 442 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2003 | 588 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2004 | 695 | 0.010 |
Why?
| | Protein Transport | 1 | 2002 | 395 | 0.010 |
Why?
| | Salmonella typhimurium | 1 | 2002 | 164 | 0.010 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2000 | 133 | 0.010 |
Why?
| | Kinetics | 1 | 2003 | 1551 | 0.010 |
Why?
| | Antigens, CD1d | 1 | 1999 | 63 | 0.010 |
Why?
| | Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 1999 | 6 | 0.010 |
Why?
| | Swine | 1 | 2002 | 700 | 0.010 |
Why?
| | Ear | 1 | 1999 | 32 | 0.010 |
Why?
| | Barium Sulfate | 1 | 1999 | 15 | 0.010 |
Why?
| | Cytoplasm | 1 | 1999 | 255 | 0.010 |
Why?
| | Cross-Linking Reagents | 1 | 1999 | 181 | 0.010 |
Why?
| | Tyrosine | 1 | 1999 | 214 | 0.010 |
Why?
| | Capillary Permeability | 1 | 1999 | 139 | 0.010 |
Why?
| | Enema | 1 | 1999 | 38 | 0.010 |
Why?
| | Cell Membrane | 1 | 2002 | 680 | 0.010 |
Why?
| | Milk | 1 | 1999 | 124 | 0.010 |
Why?
| | Rectum | 1 | 1999 | 153 | 0.010 |
Why?
| | Vasodilator Agents | 1 | 1999 | 302 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2000 | 1982 | 0.010 |
Why?
| | Serotonin Antagonists | 1 | 1996 | 30 | 0.010 |
Why?
| | Hypersensitivity, Delayed | 1 | 1996 | 27 | 0.010 |
Why?
| | Receptors, IgE | 1 | 1996 | 40 | 0.010 |
Why?
| | Contrast Media | 1 | 1999 | 345 | 0.010 |
Why?
| | Apoptosis | 1 | 2004 | 2363 | 0.010 |
Why?
| | Cell Count | 1 | 1996 | 303 | 0.010 |
Why?
| | Drug Synergism | 1 | 1995 | 317 | 0.010 |
Why?
| | Cefuroxime | 1 | 1993 | 2 | 0.010 |
Why?
| | Serotyping | 1 | 1993 | 28 | 0.010 |
Why?
| | Cellulitis | 1 | 1993 | 45 | 0.010 |
Why?
| | Eye Infections, Bacterial | 1 | 1993 | 26 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1993 | 318 | 0.010 |
Why?
| | Immunoblotting | 1 | 1993 | 283 | 0.010 |
Why?
| | Immunophenotyping | 1 | 1993 | 274 | 0.010 |
Why?
| | Bacteremia | 1 | 1993 | 160 | 0.010 |
Why?
| | Skin | 1 | 1995 | 655 | 0.010 |
Why?
| | Airway Obstruction | 1 | 1987 | 168 | 0.000 |
Why?
| | Neoplasm Recurrence, Local | 1 | 1987 | 859 | 0.000 |
Why?
|
|
Furuta's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|